Our study found that four hypoxia-immune genes, namely, AKT1, CLDN3, ISG20, and TGFB2, were promising candidates for diagnostic and therapeutic targets in MMD by combining bioinformatics methods including immune infiltration, high-throughput sequencing, and machine learning. The gene discussed is TGFB2; the disease is multiminicore myopathy.